Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase 3 Study

Documenti analoghi

• Effects of Secukinumab on Enthesiophyte and Erosion Progression in Psoriatic Arthritis: A One‐Year Double‐Blind, Randomized, Placebo‐Controlled Trial Using High‐Resolution Peripheral Quantitative Computed Tomography
  di: Yingzhao Jin, et al.
  Pubblicazione: (2025)
• Global Recruiting Patterns and Placebo Response Rates in Clinical Trials of Psoriatic Arthritis and Plaque Psoriasis
  di: Andreas Kerschbaumer, et al.
  Pubblicazione: (2025)
• Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial
  di: Joseph F. Merola, et al.
  Pubblicazione: (2026)
• Familial Aggregation in Psoriatic Arthritis: Phenotypic Differences in Patients With and Without a Family History of Psoriatic Disease
  di: Catherine Howe, et al.
  Pubblicazione: (2025)
• Development of Extramusculoskeletal Manifestations in Upadacitinib‐Treated Patients With Psoriatic Arthritis or Axial Spondyloarthritis
  di: Denis Poddubnyy, et al.
  Pubblicazione: (2025)